Compare Aurobindo Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC PHARMA AUROBINDO PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 19.8 16.6 119.3% View Chart
P/BV x 4.3 6.6 64.9% View Chart
Dividend Yield % 0.2 0.6 42.5%  

Financials

 AUROBINDO PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs830664 125.0%   
Low Rs527412 127.8%   
Sales per share (Unadj.) Rs333.9208.7 160.0%  
Earnings per share (Unadj.) Rs40.431.0 130.2%  
Cash flow per share (Unadj.) Rs51.837.1 139.5%  
Dividends per share (Unadj.) Rs2.505.50 45.5%  
Dividend yield (eoy) %0.41.0 36.1%  
Book value per share (Unadj.) Rs237.1144.2 164.4%  
Shares outstanding (eoy) m585.91188.52 310.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.6 78.8%   
Avg P/E ratio x16.817.4 96.8%  
P/CF ratio (eoy) x13.114.5 90.4%  
Price / Book Value ratio x2.93.7 76.7%  
Dividend payout %6.217.7 34.9%   
Avg Mkt Cap Rs m397,569101,461 391.8%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,8497,467 346.2%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,63639,347 497.2%  
Other income Rs m1,55394 1,655.9%   
Total revenues Rs m197,18939,441 500.0%   
Gross profit Rs m39,5198,736 452.4%  
Depreciation Rs m6,6801,152 579.7%   
Interest Rs m2,626184 1,426.4%   
Profit before tax Rs m31,7677,493 423.9%   
Minority Interest Rs m2711 250.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2691,568 463.7%   
Profit after tax Rs m23,6455,844 404.6%  
Gross profit margin %20.222.2 91.0%  
Effective tax rate %22.920.9 109.4%   
Net profit margin %12.114.9 81.4%  
BALANCE SHEET DATA
Current assets Rs m153,64519,577 784.8%   
Current liabilities Rs m120,42914,896 808.5%   
Net working cap to sales %17.011.9 142.7%  
Current ratio x1.31.3 97.1%  
Inventory Days Days13590 150.7%  
Debtors Days Days6445 140.4%  
Net fixed assets Rs m103,90927,097 383.5%   
Share capital Rs m586377 155.4%   
"Free" reserves Rs m138,32226,811 515.9%   
Net worth Rs m138,90827,188 510.9%   
Long term debt Rs m1,8004,993 36.0%   
Total assets Rs m264,54447,778 553.7%  
Interest coverage x13.141.7 31.4%   
Debt to equity ratio x00.2 7.1%  
Sales to assets ratio x0.70.8 89.8%   
Return on assets %9.912.6 78.7%  
Return on equity %17.021.5 79.2%  
Return on capital %23.823.6 101.0%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31619,453 500.3%   
Fx outflow Rs m40,5896,065 669.3%   
Net fx Rs m56,72713,388 423.7%   
CASH FLOW
From Operations Rs m16,2208,120 199.8%  
From Investments Rs m-28,768-7,556 380.7%  
From Financial Activity Rs m19,191590 3,250.4%  
Net Cashflow Rs m6,6561,153 577.2%  

Share Holding

Indian Promoters % 54.1 74.1 73.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.9 274.1%  
FIIs % 27.7 9.1 304.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 13.9 73.4%  
Shareholders   69,601 49,328 141.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   UNICHEM LAB  SUN PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 12, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS